Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Novartis International AG
WARNING LETTER
•Novartis International AG•August 4, 2011

Novartis International AG – FDA Warning Letter, Aug 4, 2011

Record Details

FDA issued a Warning Letter to Novartis International AG following inspections from April to August 2011 at its Sandoz facilities in Broomfield, Colorado; Wilson, North Carolina; and Boucherville, Quebec, Canada. The inspections revealed significant Current Good Manufacturing Practice (CGMP) violations (21 CFR Parts 210 and 211), rendering drug products adulterated. Additionally, Sandoz Canada Inc. failed to submit NDA Field Alert Reports (FARs) as required by 21 CFR § 314.81(b)(1)(ii).

Specific CGMP violations included inadequate procedures to prevent microbiological contamination, insufficient investigation of batch failures (e.g., crystallization), and failure to conduct identity tests or validate supplier analyses at Sandoz Canada. At Sandoz Broomfield, deficiencies involved inadequate production/process control procedures (equipment validation), incomplete batch failure investigations, and poor equipment cleaning. Sandoz Wilson also had inadequate production/process control procedures due to unvalidated equipment usage. The FAR violation at Sandoz Canada stemmed from not reporting crystallization complaints and stability failures within three working days.

FDA noted these were often repeat violations, indicating Novartis's failure to implement global and sustainable corrective actions and an ineffective quality system. The company is required to promptly correct all violations, provide a written response within fifteen working days detailing corrective actions and supporting documentation, and schedule a regulatory meeting within five days to discuss plans and corporate involvement. Failure to comply may result in withholding new drug application approvals, refusal of product admission into the U.S., legal action, and impact on federal contracts.

Company
Novartis International AG
Inspection date
August 4, 2011
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Donald DeGolyer
  • Khalid Nasim
  • Jon Rushord
  • Yves Moinard
  • Steven J. Lynn
View Company Profile

ID · 9cca41b2-a9c6-43c9-933d-5d4538d17b97

Violation Codes9
21 CFR 21021 CFR 21121 CFR 314.81(b)(1)(ii)21 U.S.C. 355(k)21 U.S.C. 381(a)(3)FD&C Act 501(a)(2)(B)FD&C Act 505(k)FD&C Act 801(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novartis International AG
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.